Abbott Laboratories Management

Management Kriterienprüfungen 3/4

Abbott Laboratories CEO ist Robert Ford , ernannt in Oct 2018, hat eine Amtszeit von 6.08 Jahren. Die jährliche Gesamtvergütung beträgt $23.27M , bestehend aus 6.4% Gehalt und 93.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.024% der Aktien des Unternehmens, im Wert von $48.76M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.8 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Robert Ford

Geschäftsführender

US$23.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts6.4%
Amtszeit als Geschäftsführer6.1yrs
Eigentum des Geschäftsführers0.02%
Durchschnittliche Amtszeit des Managements5.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.8yrs

Jüngste Management Updates

Recent updates

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Oct 31
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Oct 11
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27
Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Jun 04
Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Jun 04

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

May 18

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Apr 17

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Apr 15
Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Mar 21

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Mar 19
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Mar 06
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Feb 27

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Feb 08
Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

Jan 29

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26
The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Robert Ford im Vergleich zu den Einnahmen von Abbott Laboratories verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$6b

Jun 30 2024n/an/a

US$6b

Mar 31 2024n/an/a

US$6b

Dec 31 2023US$23mUS$2m

US$6b

Sep 30 2023n/an/a

US$5b

Jun 30 2023n/an/a

US$5b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$22mUS$2m

US$7b

Sep 30 2022n/an/a

US$8b

Jun 30 2022n/an/a

US$9b

Mar 31 2022n/an/a

US$8b

Dec 31 2021US$25mUS$1m

US$7b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$6b

Dec 31 2020US$20mUS$1m

US$4b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$3b

Mar 31 2020n/an/a

US$4b

Dec 31 2019US$12mUS$1m

US$4b

Sep 30 2019n/an/a

US$3b

Jun 30 2019n/an/a

US$3b

Mar 31 2019n/an/a

US$3b

Dec 31 2018US$8mUS$784k

US$2b

Sep 30 2018n/an/a

US$802m

Jun 30 2018n/an/a

US$812m

Mar 31 2018n/an/a

US$365m

Dec 31 2017US$5mUS$675k

US$344m

Vergütung im Vergleich zum Markt: RobertDie Gesamtvergütung ($USD23.27M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.67M).

Entschädigung vs. Einkommen: RobertDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Robert Ford (50 yo)

6.1yrs

Amtszeit

US$23,268,171

Vergütung

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Robert Ford
Chairman of the Board6.1yrsUS$23.27m0.024%
$ 48.8m
Philip Boudreau
CFO & Executive VP of Finance1.2yrsUS$3.32m0.0023%
$ 4.6m
Hubert Allen
Executive VP11.8yrsUS$7.42m0.011%
$ 21.6m
Daniel Salvadori
Executive VP and Group President of Established Pharmaceuticals & Nutritional Products10.2yrsUS$5.93m0.0073%
$ 14.7m
Lisa Earnhardt
Executive VP & Group President of Medical Devices5.8yrsUS$5.50m0.0035%
$ 7.2m
Sabina Ewing
Senior VP of Business & Technology Services and Chief Information Officerless than a yearkeine Datenkeine Daten
Michael Comilla
Vice President of Investor Relations.no datakeine Datenkeine Daten
Erica Battaglia
VP and Chief Ethics & Compliance Officerno datakeine Datenkeine Daten
Melissa Brotz
Vice President of Public Affairs & Corporate Marketingno datakeine Datenkeine Daten
Christopher Scoggins
Senior Vice President of Commercial Operations1.8yrskeine Datenkeine Daten
Mary Moreland
Executive Vice President of Human Resources5.3yrskeine Daten0.0059%
$ 12.0m
Jared Watkin
Executive Vice President of Diabetes Care9.4yrskeine Daten0.0042%
$ 8.4m

5.8yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: ABTDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Robert Ford
Chairman of the Board5yrsUS$23.27m0.024%
$ 48.8m
Daniel Starks
Independent Director7.8yrsUS$349.29k0.39%
$ 783.7m
John Stratton
Independent Director7.8yrsUS$341.96k0.00020%
$ 405.2k
Nancy McKinstry
Lead Independent Director12.9yrsUS$405.96k0.00027%
$ 547.0k
Michael Roman
Independent Director3.6yrsUS$337.96k0%
$ 0
Robert Alpern
Independent Director16.1yrsUS$441.44k0%
$ 0
Michael O'Grady
Independent Director1.6yrsUS$283.96k0%
$ 0
Michelle Kumbier
Independent Director6.4yrsUS$331.96k0.00018%
$ 364.7k
Sally Blount
Independent Director12.9yrsUS$362.60k0.00015%
$ 303.9k
Claire Babineaux-Fontenot
Independent Director2.2yrsUS$354.96k0%
$ 0
Darren McDew
Independent Director5.2yrsUS$331.19k0%
$ 0
Patricia Gonzalez
Independent Director3.3yrsUS$356.96k0%
$ 0

5.8yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: ABTDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).